Bill Commons

NY A 7920

in committee

Limits the substitution of abuse-deterrent analgesic opioid drug products for analgesic opioids lacking such technology

New York · 2025-2026 Regular Session · lower

Quick answers

Did NY A 7920 pass?

Not yet. NY A 7920 is in committee as of 2026-01-07 and has not come to a final vote. Latest recorded action (2026-01-07): REFERRED TO INSURANCE

What is NY A 7920 about?

Provides for patient access to FDA approved abuse-deterrent technology to help combat opioid abuse.

Who sponsors NY A 7920?

Matthew Slater is the primary sponsor of NY A 7920, joined by 4 cosponsors.

Description

Provides for patient access to FDA approved abuse-deterrent technology to help combat opioid abuse.

Introduced
Latest action
2026-01-07 — REFERRED TO INSURANCE
Bill type
bill
Last updated

Sponsors

  • Matthew Slaterprimary
  • Angelo J. Morinellocosponsor
  • Robert Smullencosponsor
  • David McDonoughcosponsor
  • Keith Browncosponsor

Committees

Not provided by source.

Action timeline

  1. 2025-04-11

    REFERRED TO INSURANCE

    referral-committee

  2. 2026-01-07

    REFERRED TO INSURANCE

    referral-committee

Versions

Documents

Votes

Not provided by source.

Related bills

  • Prior session: S 6962not in this corpus
  • Prior session: S 7009not in this corpus
  • Prior session: S 3272not in this corpus
  • Prior session: S 6180not in this corpus
  • Prior session: S 4754not in this corpus
  • Companion bill: S 6937

Official source

Attribution

Data from openstates_bulk_csv, retrieved 2026-07-24T05:28:30.722574Z

Inspect retained evidence for changes recorded after evidence tracking began:

Session-wide evidence can include changes to other bills:

Use this data

Every field on this page is available from the free public API — no key or licence required. Fetch this bill as JSON: GET /api/v1/bills?jurisdiction=NY&identifier=A 7920. See the API docs or the MCP server for AI assistants.

Known limitations

  • Sponsor party and chamber affiliation are not yet captured by this API.
  • Committee referrals are not yet captured.

See the methodology page for data sources and limitations.